Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ketevan Siradze

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Bioanalysis|February 12, 2021
Characterization of robust immune responses to a bispecific antibody, a novel class of antibody therapeuticsKun Peng, Ketevan Siradze, Saloumeh Kadkhodayan Fischer
Journal of Pharmaceutical and Biomedical Analysis|November 2, 2010
Clinical immunogenicity specificity assessments: a platform evaluationKun Peng, Ketevan Siradze, Valerie Quarmby, et al.
Journal of Immunological Methods|October 10, 2023
Evaluation of multiple immunoassay formats for detection of anti-drug antibodies to zinpentraxin alfaXiaoyun Yang, Ketevan Siradze, Gizette Sperinde, et al.
The AAPS Journal|December 15, 2018
Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352AKun Peng, Yehong Wang, Ketevan Siradze, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 24, 2024
A generic anti-drug antibody assay for monoclonal antibody therapeutics with broad dynamic range eliminates the need for titer evaluation in preclinical studiesHao Li, Alejandro R Foley, Jeongsup Shim, et al.
The AAPS Journal|January 24, 2024
Successful Development of Nonclinical Anti-Drug Antibody Assays to Support Zinpentraxin Alfa Reproductive Toxicology StudiesAudrey Arjomandi, Ketevan Siradze, Melissa Cheu, et al.
The AAPS Journal|June 6, 2025
Factors Impacting the Immunogenicity of Etrolizumab & Clinical ConsequencesGizette Sperinde, Yenny Webb-Vargas, Zicheng Hu, et al.
Mabs|July 6, 2021
An integrated approach for characterizing immunogenic responses toward a bispecific antibodySivan Cohen, Shan Chung, Christoph Spiess, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Bioanalysis|February 12, 2021
Characterization of robust immune responses to a bispecific antibody, a novel class of antibody therapeuticsKun Peng, Ketevan Siradze, Saloumeh Kadkhodayan Fischer
Journal of Pharmaceutical and Biomedical Analysis|November 2, 2010
Clinical immunogenicity specificity assessments: a platform evaluationKun Peng, Ketevan Siradze, Valerie Quarmby, et al.
Journal of Immunological Methods|October 10, 2023
Evaluation of multiple immunoassay formats for detection of anti-drug antibodies to zinpentraxin alfaXiaoyun Yang, Ketevan Siradze, Gizette Sperinde, et al.
The AAPS Journal|December 15, 2018
Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352AKun Peng, Yehong Wang, Ketevan Siradze, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 24, 2024
A generic anti-drug antibody assay for monoclonal antibody therapeutics with broad dynamic range eliminates the need for titer evaluation in preclinical studiesHao Li, Alejandro R Foley, Jeongsup Shim, et al.
The AAPS Journal|January 24, 2024
Successful Development of Nonclinical Anti-Drug Antibody Assays to Support Zinpentraxin Alfa Reproductive Toxicology StudiesAudrey Arjomandi, Ketevan Siradze, Melissa Cheu, et al.
The AAPS Journal|June 6, 2025
Factors Impacting the Immunogenicity of Etrolizumab & Clinical ConsequencesGizette Sperinde, Yenny Webb-Vargas, Zicheng Hu, et al.
Mabs|July 6, 2021
An integrated approach for characterizing immunogenic responses toward a bispecific antibodySivan Cohen, Shan Chung, Christoph Spiess, et al.
Pageof 1